Myeloid Derived Suppressor Cells Control by Signal Regulatory Protein-alpha: Investigation in Hepatocellular Carcinoma

Nantes University Hospital30 enrolled

Overview

project is to study and develop anti-Signal Regulatory Protein α (SIRPα) antibodies (Ab) as a new immunotherapy strategy in cancer. Samples harvested from hepatocellular carcinoma (HCC) and ovarian cancer patients will be used in evaluation of the SIRP-CD47 expression and of the effect of the anti-human Signal Regulatory Protein (hSIRP) Ab on various cellular types from patients and healthy volunteers.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Hepatocellular Carcinoma

Interventions

Collection of human samplesPROCEDURE

Several types of samples will be used to test the effect of the drug candidate

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * adult * HCC patients (all BCLC stages accepted) * patient consent for the use of their biological samples Exclusion Criteria: * patient with other cancers * hepatitis C or B positive * HCC treatment by chemo-embolization under 3 months * under Sorafenib treatment within the month prior to collection * underage or under guardianship patients

Outcomes

Primary Outcomes

evaluation of the SIRP/CD47 expression

samples harvested from HCC and ovarian cancer patients will be used in evaluation of the SIRP-CD47 expression and of the effect of the anti-hSIRP Ab on various cellular types from patients

Time frame: baseline

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.